The structural requirements for sympathomimetic cardio-acceleration and increased contraction force differ from those optimal for bronchodilator action, suggesting receptor population heterogeneity.
Answers are grounded in this paper and cite their sources.
Suggests potential for selective cardiac sympathomimetics distinct from bronchodilators in preclinical models; leaves open clinical translation of receptor heterogeneity.
Cardiac stimulating actions of selected sympathomimetic amines have been compared. In the case of the β-phenethanola-mines described here, this effect was increased by substitution of a cyclopentyl or isopropyl group in the N-center. Alkyl (methyl, ethyl or propyl) substitution of the a-carbon of the side chain markedly reduced cardiac stimulation and in the case of the N-substituted catecholamines described here, disclosed differences in potency for effects on force as compared to rate. The structural requirements for initiating sympathomimetic cardio-acceleration and for increases in the force of contraction differ from those which are optimal for bronchodilator action. The receptors responding to sympathomimetic amines may consist of a population differing in sensitivity to structural variation of the agonist (and possibly also to the various antagonists).
No takes yet. Share an insight, caveat, or question.
Lands et al. (1964) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: